These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 10367679)

  • 1. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
    Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
    Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Fc2'-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice.
    Fishman A; Prus D; Belostotsky R; Lorberboum-Galski H
    Clin Exp Immunol; 2000 Mar; 119(3):398-403. PubMed ID: 10691909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.
    Sokolova EA; Stremovskiy OA; Zdobnova TA; Balalaeva IV; Deyev SM
    Acta Naturae; 2015; 7(4):93-6. PubMed ID: 26798495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal administration of gonadotropin-releasing hormone-PE40 induces castration in male rats.
    Yu L; Zhang ZF; Jing CX; Wu FL
    World J Gastroenterol; 2008 Apr; 14(13):2106-9. PubMed ID: 18395915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological hormone atrophy by gonadotropin-based drug.
    Li J; Zhang J
    Int J Exp Pathol; 2006 Dec; 87(6):495-9. PubMed ID: 17222217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxins for targeted cancer therapy.
    Kreitman RJ
    AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells.
    Gong SL; Zhao G; Zhao HG; Lu WT; Liu GW; Zhu P
    World J Gastroenterol; 2004 Oct; 10(19):2870-3. PubMed ID: 15334689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing immunotoxins for cancer therapy.
    Pennell CA; Erickson HA
    Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB
    Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
    [No Abstract]   [Full Text] [Related]  

  • 10. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN; Chace DF; Trail PA; Siegall CB
    J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
    J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
    Siegall CB
    Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
    Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
    Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.